Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor

Cancer Prevention Research

Volumn 4, Issue 3, 2011, Pages 445-453

  Teraoka, Naoya ^a   Mutoh, Michihiro ^a   Takasu, Shinji ^a   Ueno, Toshiya ^a   Yamamoto, Masafumi ^a   Sugimura, Takashi ^a   Wakabayashi, Keiji ^a,b  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; CHOLESTEROL; CYCLOOXYGENASE 2; GUANOSINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; LEPTIN; LIPID; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PITAVASTATIN; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DNA BINDING; DRUG MECHANISM; DRUG SYNTHESIS; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; INTESTINE POLYP; LIPID BLOOD LEVEL; LIVER; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMALL INTESTINE; TREATMENT DURATION;

ANIMALS; CHEMOKINE CCL2; CHOLESTEROL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOTYPE; GUANOSINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; INTESTINAL POLYPS; LEPTIN; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE II; NITRO COMPOUNDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; QUINOLINES; TRIGLYCERIDES;

EID: 79955806406     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0028     Document Type: Article

References (45)

1. Slattery ML, Boucher KM, Caan BJ, Potter JD, Ma KN. Eating patterns and risk of colon cancer. Am J Epidemiol 1998;148:4-16. (Pubitemid 28317538)
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. The Japan Cancer Surveillance Research Group. Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2008;38:641-8.
3. McKeown-Eyssen G. Epidemiology of colorectal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk? Cancer Epidemiol Biomarkers Prev 1994;3:687-95.
4. Yamada K, Araki S, Tamura M, Sakai I, Takahashi Y, Kashihara H, et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998;27:794-8. (Pubitemid 28504966)
5. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003;63:6090-5. (Pubitemid 37187515)
6. Niho N, Takahashi M, Shoji Y, Takeuchi Y, Matsubara S, Sugimura T, et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR gamma ligand. Cancer Sci 2003;94:960-4. (Pubitemid 37508978)
7. Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci USA 2005;102:2970-4.
8. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 1976;29:1346-8. (Pubitemid 8018023)
9. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
10. McTavish D, Sorkin EM. Pravastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1991;42:65-89.
11. Todd PA, Goa KL. Simvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1990;40:583-607.
12. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996;51:433-59.
13. Lea AP, McTavish D. Atorvastatin: a review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997;53:828-47. (Pubitemid 27195013)
14. Olsson AG. Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Am J Cardiol 2001;87:33B-6.
15. Poynter JN, Gruber SB, Higgins RD, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92. (Pubitemid 40727085)
16. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Traetment to Prevnt Heart Attack Trial-Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
17. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS-Air Force/Texas Coronary Atherosclerosis prevention study. JAMA 1998;279:1615-22. (Pubitemid 28248586)
18. Narisawa T, Fukaura Y, Tanida N, Hasebe M, Ito M, Aizawa R. Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice. Tohoku J Exp Med 1996;180:131-8.
19. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, et al. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F344 rats. Cancer Res 2006;66:4542-6.
20. min mice. Cancer Res 2006;66:7370-77.
21. Flores NA. Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo. Curr Opin Investig Drugs 2002;3:1334-41.
22. Yasui Y, Suzuki R, Miyamoto S, Tsukamoto T, Sugie S, Kohno H, et al. A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis. Int J Cancer 2007;121:2331-9. (Pubitemid 47585616)
23. Saito Y, Yamada N, Teramoto T, Itakura H, Hata Y, Nakaya N, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002;162:373-9. (Pubitemid 34457943)
24. Iglesias P, Diez JJ. New drugs for the treatment of hypercholesterolaemia. Expert Opin Investig Drugs 2003;12:1777-89. (Pubitemid 37408126)
25. Demierre MF, Higgins PDR, Gruber SB, Hawk E, Lippman SM. Statin and cancer prevention. Nat Rev Cancer 2005;5:930-42.
26. Wang CY, Liu PY, Liao JK. Pleiotropic effedts of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44.
27. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
28. Inukai K, Nakashima Y, Watanabe M, Takata N, Sawa T, Kurihara S, et al. Regulation of adiponectin receptor gene expression in diabetic mice. Am J Endocrinol Metab 2005;288:E876-82.
29. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, et al. Resolvin E1, an endogenous lipid mediator derived from omega- 3 eicosapentanoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci USA 2005;102:7671-6.
30. Abe M, Matsuda M, Kobayashi H, Miyata Y, Nakayama Y, Komuro R, et al. Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-bpathway in macrophage. Arterioscler Thromb Vasc Biol 2008;28:871-7. (Pubitemid 351544101)
31. Mutoh M, Niho N, Komiya M, Takahashi M, Ohtsubo R, Nakatogawa K, et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice. Carcinogenesis 2008;29:824-9. (Pubitemid 351494171)
32. Yano M, Matsumura T, Senokuchi T, Ishii N, Murata Y, Taketa K, et al. Statin activate peroxisome proliferators-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circ Res 2008;100:1442-51. (Pubitemid 46834756)
33. Kita T, Brown MS, Goldstein JL. Feedback regulation of 3-hydroxy-3- methylglutaryl Coenzyme a reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest 1980;66:1094-100. (Pubitemid 11233811)
34. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T,et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3- methylglutaryl-coenzyme A reductase. Arzneim-Forsch/Drug Res 1997;47:904-9.
35. Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S, et al. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004;43:1214-20. (Pubitemid 38691742)
36. Lee JY, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Simvastatin inhibits NF-κB signaling in intestinal epithelial cells and amelio-rates2288; acute murine colitis. Int Immunopharmacol 2007;7:241-8. (Pubitemid 46037564)
37. Wang J, Kitajima I. Pitavastatin inactivate NF-κB and decreases IL-6 production through Rho kinase pathway in MCF-7. Oncol Rep 2007;17:1149-54.
38. Nakatsugi S, Fukutake M, Takahashi M, Fukuda K, Isoi T, Taniguchi Y, et al. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res 1997;88:1117-20. (Pubitemid 28048255)
39. Min/+ mice. Am J Physiol Regul Integr Comp Physiol 2008;294:R393-401.
40. Kohno H, Takahashi M, Yasui Y, Suzuki R, Miyamoto S, Kamanaka Y, et al. A specific inducible nitric oxide synthase inhibitor, ONO-1714 attenuates inflammation-related large bowel carcinogenesis in male ApcMin/+ mice. Int J Cancer 2007;121:506-13. (Pubitemid 46986482)
41. Masuda M, Nishino H, Ohshima H. Formation of 8-nitroguanosine in cellular RNA as a biomarker of exposure to reactive nitrogen species. Chem Biol Interact 2002;139:187-97. (Pubitemid 34131717)
42. Leung WK, Bai AHC, Chan VYW, Yu J, Chan MWY, To K-F, et al. Effect of peroxisome proliferators activated receptor g ligands on growth and gene expression profiles of gastric cancer cells. Gut 2004;53:331-8. (Pubitemid 38241325)
43. Maeda T, Horiuchi N. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. J Biochem 2009;145:771-81.
44. Rodríguez A, Fortuño A, Gómez-Ambrosi J, Zalba G, Díez J, Fr€uhbeck G. The inhibitory effect of leptin on angiotensin II-induced vasocon-striction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology 2007;148:324-33.
45. Niho N, Mutoh M, Komiya M, Ohta T, Sugimura T, Wakabayashi K. Improvement of hyperlipidemia by indomethacin in Min mice. Int J Cancer 2007;121:1665-9. (Pubitemid 47417281)